InvestorsHub Logo
Followers 1
Posts 38
Boards Moderated 0
Alias Born 10/30/2009

Re: None

Tuesday, 02/28/2017 4:34:29 PM

Tuesday, February 28, 2017 4:34:29 PM

Post# of 12137
Kite Pharma is up 25% due to the pivotal trial of patients with aggressive non-Hodgkin lymphoma. It appears that the results were exceptional. This should bode well for CYRX. Kite appears to be ahead of Juno and while it's still early Kite seems to be in first place on the path to get their CAR-T drug to market.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYRX News